Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Haematological cancer

Beyond the R² horizon: new triplet regimens for relapsed and/or refractory follicular lymphoma

Nature Reviews Clinical Oncology (2026)Cite this article

Subjects

Novel immunotherapy combinations are now available for second or later-line therapy for follicular lymphoma. The addition of tafasitamab, an anti-CD19 antibody, or epcoritamab, a CD20 × CD3 bispecific antibody, to lenalidomide–rituximab (R2) has demonstrated promising efficacy. Herein, I compare recent phase III trials testing each combination and discuss their practical implications.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

References

  1. Leonard, J. P. et al. AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J. Clin. Oncol. 37, 1188–1199 (2019).

    Article  PubMed  PubMed Central  Google Scholar 

  2. Sehn, L. H. et al. Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial. Lancet 407, 133–146 (2026).

    Article  PubMed  Google Scholar 

  3. Falchi, L. et al. Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial. Lancet 407, 161–173 (2026).

    Article  PubMed  Google Scholar 

  4. Linton, K. M. et al. Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study. Lancet Haematol. 11, e593–e605 (2024).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Southwest Oncology, Mercy CommonSpirit, Durango, CO, USA

    Loretta J. Nastoupil

Authors
  1. Loretta J. Nastoupil
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Loretta J. Nastoupil.

Ethics declarations

Competing interests

L.J.N. has received honoraria for participation in advisory boards from AstraZeneca, BMS, Genentech, Genmab, Johnson & Johnson, Novartis and Regeneron; and served as principal investigator for the CELESTIMO trial.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nastoupil, L.J. Beyond the R² horizon: new triplet regimens for relapsed and/or refractory follicular lymphoma. Nat Rev Clin Oncol (2026). https://doi.org/10.1038/s41571-026-01125-2

Download citation

  • Published:

  • Version of record:

  • DOI: https://doi.org/10.1038/s41571-026-01125-2

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer